

![]() |
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. |
|
Authors | ![]() | |
Published in | Journal of hepatology. 2011, vol. 55, no. 5, p. 980-8 | |
Abstract | Single nucleotide polymorphisms (SNPs) associated with IL28B influence the outcome of peginterferon-α/ribavirin therapy of chronic hepatitis C virus (HCV) infection. We analyzed the kinetics of HCV RNA during therapy as a function of IL28B SNPs. | |
Keywords | Adult — Alleles — Antiviral Agents/therapeutic use — Female — Gene Frequency — Genotype — Hepacivirus/genetics/physiology — Hepatitis C, Chronic/drug therapy/genetics — Humans — Interferon-alpha/therapeutic use — Interleukins/genetics — Male — Middle Aged — Multivariate Analysis — Polyethylene Glycols/therapeutic use — Polymorphism, Single Nucleotide/genetics — RNA, Viral/blood — Recombinant Proteins/therapeutic use — Ribavirin/therapeutic use — Time Factors | |
Identifiers | PMID: 21354446 | |
Full text | ||
Structures | ||
Research group | Etudes et traitement de l'hépatite C et B (554) | |
Citation (ISO format) | BOCHUD, Pierre-Yves et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. In: Journal of hepatology, 2011, vol. 55, n° 5, p. 980-8. doi: 10.1016/j.jhep.2011.01.050 https://archive-ouverte.unige.ch/unige:25376 |